期刊
PROGRESS IN CARDIOVASCULAR DISEASES
卷 75, 期 -, 页码 4-11出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pcad.2022.11.009
关键词
Lipids; Guidelines; Adherence; Implementation
Guidelines recommend intensive lifestyle intervention and statin/non-statin pharmacotherapy to lower cholesterol and reduce ASCVD risk. However, there is a significant treatment gap and more research is needed to address barriers to guideline implementation.
Guidelines support lowering cholesterol to decrease atherosclerotic cardiovascular disease (ASCVD) risk across the entire lifespan with intensive lifestyle intervention, as well as statin and non-statin pharmacotherapy for those at highest risk. Modest improvements in the initiation, use, and adherence to statin therapy in patients with ASCVD have occurred over the past decades. However, studies continue to document a less than desired implementation of guidelines highlighting a substantial and persistent treatment gap. The success of implementation depends on the consideration of a variety of barriers that exist throughout the healthcare delivery system. Further research is needed to comprehensively evaluate these barriers in order to develop appropriate and sustainable interventions to improve guideline implementation. (C) 2022 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据